Kezar Life Sciences

Quarterly Financials

Values in thousands2025-09-302025-06-302025-03-312024-12-31
Revenue
$0
$0
$0
$1,042
Gross Profit
-227
-251
521
EBITDA
-11,000
-13,159
-15,958
-19,570
EBIT
-11,227
-13,402
-16,209
-19,829
Net Income
-11,227
-13,704
-16,556
-20,218
Net Change In Cash
0
0
0
1,042
Free Cash Flow
-9,830
-12,795
-17,198
-16,836
Cash
38,935
34,367
37,002
41,749
Basic Shares
7,323
7,311
7,305
7,300

Annual Financials

Values in thousands2024-12-312023-12-312022-12-312021-12-31
Revenue
$0
$7,000
$0
$0
Gross Profit
-1,040
7,000
-1,022
-1,510
EBITDA
-81,103
-99,254
-70,139
-52,961
EBIT
-82,143
-100,320
-71,162
-54,471
Net Income
-83,736
-101,870
-65,316
-54,630
Net Change In Cash
0
7,000
0
0
Cost of Revenue
-22,377
41,704
Free Cash Flow
-74,241
-83,455
-60,424
-42,753
Cash
41,749
35,493
40,456
62,882
Basic Shares
72,902
72,553
67,368
52,759

Earnings Calls

QuarterEPS
2025-09-30
-$1.53
2025-06-30
-$1.87
2025-03-31
-$2
2024-12-31
-$3